Splash Pharmaceuticals — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Splash Pharmaceuticals is a private, clinical-stage biotech based in San Diego, founded in 2015, with a focus on targeting CD44 for cancer and arthritis. Its lead asset, SPL-108, has generated promising safety and efficacy data across multiple trials, positioning the company for potential partnerships. The firm operates as a pre-revenue therapeutics developer seeking collaboration to advance its programs.

OncologyArthritis

Technology Platform

Novel strategy to target CD44 safely and effectively for oncology and arthritis, built on decades of experience and data.

Opportunities

A successful CD44-targeted therapy could address large unmet needs in treatment-resistant cancers and arthritis, representing multi-billion dollar market opportunities.

Demonstrating efficacy in multiple indications would significantly increase the asset's value and partnership appeal.

Risk Factors

High clinical risk associated with historically challenging CD44 target; financial risk due to dependence on securing a partnership for further development; operational risk from a lean, non-transparent corporate structure.

Competitive Landscape

The competitive landscape for CD44 targeting is active but has not yet yielded an approved therapy, indicating both high unmet need and high development difficulty. Splash competes with other biotechs and academic groups exploring anti-CD44 antibodies, peptides, and other modalities across oncology and inflammation.

More companies in Oncology (General) →More companies in United States →